Home Ingredients DermaNiA® (Niacinamide for Skin Health — Sabinsa)
Hair, Skin & Nails

DermaNiA® (Niacinamide for Skin Health — Sabinsa)

Evidence Level
Strong
2 Clinical Trials
6 Documented Benefits
4/5 Evidence Score

DermaNiA® is Sabinsa's branded niacinamide (nicotinamide, vitamin B3) for skin health applications. Niacinamide has substantial published evidence for skin applications, primarily via TOPICAL use — multiple RCTs document improvements in hyperpigmentation, fine lines, wrinkles, skin barrier function, sebum production, and acne when applied at 2-5% topical concentrations. ORAL niacinamide for skin has more limited but notable evidence: the landmark Chen 2015 trial (n=386, 1 year, NEJM) showed 500 mg twice daily reduced new non-melanoma skin cancer (NMSC) incidence by 23% in high-risk patients with prior NMSC history. The clinical oral dose for NMSC prevention is 500 mg twice daily; lower doses (100-500 mg/day) are common in skin-health supplements. Honest framing: oral niacinamide for general skin appearance (anti-aging, hyperpigmentation) has less robust evidence than topical niacinamide — for those endpoints, topical application is the better-evidenced delivery route. Oral niacinamide's most validated indication is NMSC chemoprevention in high-risk patients.

Studied Dose NMSC prevention (oral): 500 mg twice daily (1,000 mg/day total) — the Chen 2015 ONTRAC trial protocol. General skin support (oral): 100-500 mg/day. Topical niacinamide: 2-5% concentrations in creams/serums (the more robust evidence base for general skin appearance endpoints). Niacinamide is well-tolerated up to 3,000 mg/day in oral pharmaceutical use (e.g., bullous pemphigoid).
Active Compound Niacinamide (nicotinamide), the amide form of vitamin B3 — distinct from niacin (nicotinic acid) which causes flushing. Niacinamide is a precursor to NAD+ and NADP+, essential cellular coenzymes for redox reactions, DNA repair, and energy metabolism. Sabinsa's DermaNiA® specification not publicly detailed beyond marketing positioning as a high-purity niacinamide for skin applications.

Benefits

Non-melanoma skin cancer prevention — Chen 2015

ONTRAC trial (NEJM): 386 patients with history of NMSC randomized to oral niacinamide 500 mg twice daily vs placebo for 12 months. Outcome: 23% reduction in new NMSC incidence (basal cell + squamous cell carcinomas), 20% reduction in actinic keratoses. Strongest oral niacinamide evidence; standard of care for high-risk NMSC patients in dermatology guidelines. Effect disappears within 6 months of discontinuation.

Supported by Trial 1

Hyperpigmentation reduction (topical)

Multiple RCTs document 2-5% topical niacinamide significantly reduces facial hyperpigmented spots vs vehicle control. Mechanism: inhibits melanosome transfer from melanocytes to keratinocytes. Effect is dose-dependent and reversible. Evidence stronger than for oral niacinamide for this endpoint.

Supported by Trial 2

Skin barrier function improvement (topical)

Topical niacinamide upregulates ceramide, free fatty acid, and cholesterol synthesis in keratinocytes — improving skin barrier integrity. Documented in RCTs as reduced transepidermal water loss and improved skin hydration. Particularly relevant for sensitive skin and post-inflammatory barrier compromise.

Supported by Trial 2

Anti-aging skin improvements (topical)

Bissett 2005 8-week RCT (Olay-funded but methodologically sound): 5% topical niacinamide vs vehicle control improved fine lines/wrinkles, hyperpigmented spots, texture, red blotchiness, and sallowness vs control. Mechanism: NAD+ restoration in aging skin where NAD+ levels decline.

Supported by Trial 2

Acne treatment (topical and oral)

Topical 4% niacinamide has shown efficacy comparable to clindamycin in moderate inflammatory acne. Mechanism: anti-inflammatory, sebum-reducing, antimicrobial properties without antibiotic resistance concerns. Oral niacinamide also has acne evidence at 500-750 mg/day, often in multi-ingredient formulations.

Supported by Trial 2, Trial 1

NAD+ precursor pathway

Niacinamide is converted to NAD+ (nicotinamide adenine dinucleotide), the key cellular coenzyme for redox reactions, DNA repair (via PARP enzymes), and energy metabolism. NAD+ levels decline with age; skin NAD+ specifically decreases with UV exposure and oxidative stress. Restoring NAD+ via niacinamide supports broader cellular maintenance.

Supported by Trial 1

Mechanism of action

1

NAD+ pool restoration

Niacinamide is the most direct precursor to NAD+ via the salvage pathway, bypassing the slower de novo synthesis from tryptophan. Increased NAD+ supports mitochondrial energy production, DNA repair via PARP enzymes, and sirtuin activity. Distinct from precursors like NR (nicotinamide riboside) which feed the same pathway via a different entry point.

2

Melanosome transfer inhibition (topical)

Niacinamide inhibits the transfer of mature melanosomes from melanocytes to surrounding keratinocytes — the rate-limiting step in skin pigmentation. Distinct from tyrosinase inhibition (hydroquinone, kojic acid) which prevents melanin synthesis. Both mechanisms can reduce hyperpigmentation, but niacinamide's approach is gentler and has lower irritation profile.

3

Anti-inflammatory and immunomodulatory effects

Niacinamide inhibits poly(ADP-ribose) polymerase (PARP) hyperactivation in UV-damaged cells, reducing inflammatory cytokine release. Also suppresses neutrophil chemotaxis and Th17 inflammatory responses — relevant to acne, rosacea, and inflammatory dermatoses.

4

Photoimmunoprotection (NMSC prevention)

Oral niacinamide preserves cellular ATP after UV exposure, reduces UV-induced immunosuppression, and enhances DNA repair via PARP energy preservation. These mechanisms collectively reduce UV-mutagenesis and explain the Chen 2015 NMSC chemoprevention effect.

Clinical trials

1
ONTRAC Trial: Oral Niacinamide for NMSC Prevention — Chen 2015 (NEJM)

Phase 3 randomized double-blind placebo-controlled trial in 386 patients with ≥2 NMSCs in the previous 5 years. Intervention: niacinamide 500 mg twice daily or placebo for 12 months. Outcome: 23% reduction in new NMSC incidence (P=0.02) — primary endpoint. 13% reduction in basal cell carcinomas, 30% reduction in squamous cell carcinomas. 20% reduction in actinic keratoses. Effect disappeared within 6 months of discontinuation. Published in NEJM 2015; incorporated into dermatology clinical practice for high-NMSC-risk patients.

2
Topical Niacinamide for Hyperpigmentation — Hakozaki 2002

Left-right randomized vehicle-controlled split-face trial in 79 Japanese women with multiple types of brown hyperpigmentation. Topical niacinamide-containing product at 2% and 5% niacinamide significantly reduced facial hyperpigmented spots in dose-dependent manner. Effect reversed within 8 weeks of discontinuation. Foundational evidence for topical niacinamide in hyperpigmentation. Published in Journal of the American Academy of Dermatology.

Side effects and drug interactions

Common Potential side effects

Excellent tolerability profile at oral doses up to 1,000 mg/day.
Does NOT cause flushing (unlike niacin/nicotinic acid). This is a key distinguishing feature.
Possible mild GI effects at higher doses (>3,000 mg/day).
Rare hepatotoxicity reported at very high chronic doses (>3 g/day).
Topical niacinamide generally non-irritating, suitable even for sensitive skin.

Important Drug interactions

Anticonvulsants (carbamazepine, primidone) — niacinamide may inhibit hepatic metabolism, raising drug levels; theoretical interaction at high doses.
Metformin — chronic high-dose niacinamide may modestly affect glucose homeostasis; minimal clinical relevance at typical supplemental doses.
Statins — no significant interaction documented; niacinamide does NOT have niacin's HDL-raising lipid effects, so no lipid management interaction.
Pregnancy and lactation — niacinamide is the essential B3 vitamin form; pregnancy RDA is 18 mg/day; supplemental doses up to 500 mg/day generally considered safe but higher doses lack pregnancy-specific safety data.
Children — niacinamide is essential B3; supplementation should match age-appropriate RDA unless under medical direction.
Featured In

Symptom-specific supplement guides

✨Best Supplements for Acne💎Best Supplements for Skin Health

More Hair, Skin & Nails Ingredients

Cardiovascular
Niacin
Niacin, or vitamin B3, is a vital nutrient that supports energy production by serving as a…
Cardiovascular
Omega-3 Fatty Acids
Omega-3 fatty acids, primarily eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), an…
Immune Support
Vitamin C
Vitamin C, also known as ascorbic acid, is a water-soluble vitamin commonly used in supple…
Immune Support
Zinc
Zinc, an essential trace mineral, is commonly supplemented in forms like zinc gluconate, a…

Explore Other Ingredients

Cognitive
Ashwagandha
Ashwagandha is an adaptogenic herb that may reduce stress, enhance mood, and support overa…
Cognitive
L-Theanine
L-Theanine, an amino acid primarily found in green tea (Camellia sinensis), is commonly su…
Cognitive
Suntheanine®
Suntheanine® is a patented, 100% pure L-isomer theanine produced via an enzymatic process…

Frequently asked questions about DermaNiA® (Niacinamide for Skin Health — Sabinsa)

What is DermaNiA® (Niacinamide for Skin Health — Sabinsa)?

DermaNiA® is Sabinsa's branded niacinamide (nicotinamide, vitamin B3) for skin health applications.

What does DermaNiA® (Niacinamide for Skin Health — Sabinsa) do?

Niacinamide is the most direct precursor to NAD+ via the salvage pathway, bypassing the slower de novo synthesis from tryptophan. Increased NAD+ supports mitochondrial energy production, DNA repair via PARP enzymes, and sirtuin activity. In clinical research, DermaNiA® (Niacinamide for Skin Health — Sabinsa) has been studied for non-melanoma skin cancer prevention — chen 2015, hyperpigmentation reduction (topical), skin barrier function improvement (topical).

Who should take DermaNiA® (Niacinamide for Skin Health — Sabinsa)?

DermaNiA® (Niacinamide for Skin Health — Sabinsa) may be most relevant for people interested in hair, skin & nails. It has been clinically studied for non-melanoma skin cancer prevention — chen 2015, hyperpigmentation reduction (topical), skin barrier function improvement (topical). As with any supplement, consult your healthcare provider before starting, especially if you have medical conditions or take prescription medications.

How long does DermaNiA® (Niacinamide for Skin Health — Sabinsa) take to work?

In clinical trials, effects typically appear over 8+ weeks of consistent use. Acute or same-day effects (where applicable) typically appear within hours, but most cumulative benefits — particularly those affecting biomarkers, mood, sleep quality, or chronic symptoms — require 4-12 weeks of regular use to fully assess. If you don't notice benefit after 12 weeks at the appropriate dose, it may not be your responder.

When is the best time to take DermaNiA® (Niacinamide for Skin Health — Sabinsa)?

DermaNiA® (Niacinamide for Skin Health — Sabinsa) can typically be taken with breakfast or dinner — taking with food reduces GI sensitivity for most supplements. Specific timing matters less than daily consistency for cumulative effects. Always check product labeling and follow personalized guidance from your healthcare provider.

Is DermaNiA® (Niacinamide for Skin Health — Sabinsa) worth taking?

DermaNiA® (Niacinamide for Skin Health — Sabinsa) has strong clinical evidence (Evidence Level 4/5 on NutraSmarts) for its primary uses, with multiple randomized controlled trials and meta-analyses supporting its benefits. Whether it's worth taking depends on your specific goals, what you've already tried, your budget, and your overall supplement strategy. The honest framing: no supplement is essential for most people, and lifestyle factors (sleep, exercise, diet, stress management) typically produce larger effects than any single supplement. DermaNiA® (Niacinamide for Skin Health — Sabinsa) is most worth trying if its evidence-supported uses align with your specific goals.

What is the recommended dosage of DermaNiA® (Niacinamide for Skin Health — Sabinsa)?

The clinically studied dose for DermaNiA® (Niacinamide for Skin Health — Sabinsa) is NMSC prevention (oral): 500 mg twice daily (1,000 mg/day total) — the Chen 2015 ONTRAC trial protocol. General skin support (oral): 100-500 mg/day. Topical niacinamide: 2-5% concentrations in creams/serums (the more robust evidence base for general skin appearance endpoints). Niacinamide is well-tolerated up to 3,000 mg/day in oral pharmaceutical use (e.g., bullous pemphigoid).. Always follow product labeling and consult a healthcare provider for personalized dosing recommendations.

What is DermaNiA® (Niacinamide for Skin Health — Sabinsa) used for?

DermaNiA® (Niacinamide for Skin Health — Sabinsa) is studied for non-melanoma skin cancer prevention — chen 2015, hyperpigmentation reduction (topical), skin barrier function improvement (topical). ONTRAC trial (NEJM): 386 patients with history of NMSC randomized to oral niacinamide 500 mg twice daily vs placebo for 12 months.